KUMULUS-VAPE
23.5.2019 18:51:10 CEST | Business Wire | Press release
Kumulus Vape (ISIN FR0013419876 – MLVAP ), an online retailer specialised in the sale of electronic cigarettes and related products (devices, e-liquid and accessories), referred collectively as “e-cigarettes”, is pleased to announce the listing of its shares on the Euronext Access™ compartment in Paris by technical admission (Euronext notice PAR_20190523_05573_ACC). First listing will take place on 28 May 2019.
This initial public offering - a first in Europe’s e-cigarette space - is a new milestone in the performance trajectory of the Lyon-based company, a pioneer on this market in acceleration phase.
Kumulus Vape posted 2018 sales of €6.5 million, up 116% on 2017. Its outlook is highly auspicious, with 96% quarter-on-quarter growth in the first quarter of 2019. Kumulus Vape’s goal is clear: to become one of the French leaders in 100% online e-cigarette retail within three years.
AN E-CIGARETTE PIONEER
A CATALOGUE OF OVER 6,000
REFERENCES
Kumulus Vape is one of the top online French retailers of dedicated e-cigarette products (devices, e-liquid, DIY1 ). Its extensive catalogue of over 6,000 references caters to both “beginner” and expert e-cigarette users. Active in the fight against tobacco and a defender of the e-cigarette sector, Kumulus Vape offers an unparallelled range of high-performance products at competitive prices.
Founded in 2012, the Company rapidly ascended to become one of the leaders on this regulated sector that is increasingly recognised by the general public, health authorities (the French Economic, Social and Environmental Council - CESE) and government (French Ministry of Health).
Its model comprises two complementary activities: B2C (online sales only) and B2B (sales to a network of specialist retailers).
The group’s original activity, B2C, has grown rapidly over the last three years. Between 2016 and 2018, business has soared and the number of customers tripled. Sales (40% of total sales) also tripled over the period to reach €2.8 million in 2018.
Its B2B business (60% of total sales), which began in 2017, has also been an instant success. Today, more and more specialist retailers use Kumulus Vape for all their supplies.
A POTENTIAL MARKET WORTH OVER €800 MILLION IN FRANCE
Both activities are tapping into a huge market with a potential estimated at over €800 million in France2 . Indeed, faced with the devastating effects of tobacco, which is believed to be responsible for over seven million deaths per year worldwide3 , nearly one out of two smokers (45%) in France intends to switch to e-cigarettes by 20204 . That is over five million potential users of a product that is seen as an indispensable solution to giving up smoking.
The B2B market also has strong growth potential with as many as 2,700 points of sale that are already addressable on a highly buoyant market across France.
SUCCESS IN ACTION:
116% GROWTH IN 2018, ESTABLISHED
PROFITABILITY
All these advantages have accelerated Kumulus Vape’s take-off. The Company has doubled its sales every year since 2016, putting its average annual growth at 100% for the last three years. This performance illustrates the growing success of the Kumulus Vape produce range, as well as the Company’s ability to capture new customers on both the B2B and B2C markets.
2018 was a blockbuster year for Kumulus Vape, with sales up 116% to €6.5 million on the performance of both the B2B market (+240%) and B2C market (+54%). This strong growth is accompanied by solid profitability. EBITDA for 2018 exceeded the €400k threshold (+128% compared with 2017) for net earnings of nearly €300k (+106%).
The 2019 fiscal year began on a very positive note after sales gained 96% to €2.3 million in the first quarter.
AN AMBITION TO REACH OVER €15M IN SALES IN 2020
THE STOCK
MARKET AS AN ACCELERATOR
To facilitate its growth, in early 2019 Kumulus Vape doubled its order processing capacity by moving to new premises of 2,600 m² just outside of Lyon. This integrated logistics platform is designed to handle up to €80 million orders per year. Today Kumulus Vape is poised to accelerate its growth and intends to hit the €15 million sales mark from 2020 onwards.
To this end, it plans to hire sales representatives in France and step up its marketing and visibility, particularly via search engine optimisation. The Company will also draw on new growth drivers and find ways to expand its margins, such as boosting the share of its white-label products. Since 2016, it offers a diverse range of e-liquids (Origa, Mythik, Master DIY) that are already distributed worldwide.
TARGET: EURONEXT GROWTH
The purpose of the IPO is to raise Kumulus Vape’s profile and grow its domestic footprint.
In the long run, the Company and its shareholders are focused on increasing its free float. Kumulus Vape’s admission on Euronext Access is a first step before potentially transferring its shares to the Euronext Growth compartment.
Accordingly, 55,000 shares will be available for sale on the first day of trade, in line with the Company’s desire to encourage the growth of its free float which could soon account for 5-10% of its capital.
Rémi Baert, Chairman and Founder of Kumulus Vape, comments : “We are very pleased to be bringing to fruition what is a milestone in Kumulus Vape’s history. The market timing is ideal, given the growth of all our business activities. Today everything is in place for us to take this next step in our development and change gear in terms of ramping up our international presence from this year and the expected take-off of our B2B business. Our IPO on Euronext Access is a further step to our success and will consolidate our momentum. It will also help boost our image with the general public and institutional investors at a time when the e-cigarette is becoming an indispensable solution to giving up smoking.”
Transaction details
Listing market:
Euronext Access
ISIN
:
FR0013419876
Mnemo
: MLVAP
Listing procedure
:
Technical admission
Number of shares in registered capital:
1,988,000
Number of shares sold on the day of listing:
55,000
Sale
price per share
: €2.12
Valuation opted for listing
:
€4,214,560.00
Start of trading
: 28 May 2019
Eligibility
for PEA (equity savings plan) and SME PEA:
yes
The operation does not require approval from the AMF (French financial markets authority). Therefore, the Information Document has not been approved by the AMF. The Information Document is available free of charge at the headquarters of Kumulus Vape. It can be downloaded at www.kumulusvape.fr/investisseurs . Companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Rather, they are subject to a less extensive body of rules adapted to small growth businesses. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company of the regulated market.
Transaction partners
| Atout Capital | Advisors and Listing Sponsor | |
| Lamy Lexel | Legal advice | |
| Mazars | Statutory Auditor | |
| Actifin | Financial Communication |
About Kumulus Vape
Based in Corbas in the Metropolis of Lyon, Kumulus Vape is currently one of the French leaders in B2C distribution www.kumulusvape.fr and B2B distribution kmls.fr of e-cigarette and e-liquid products. Founded in 2012, the Company has one of the most diverse catalogues on the market with over 6,000 references and representing nearly 250 brands. Since 2016, it offers a wide range of e-liquid white labelling solutions (Origa, Mythik, Master DIY). Kumulus Vape’s 2018 sales topped €6.5 million, up 116% on 2017.
1
Do It Yourself: e-liquid base that allow users to prepare
their own recipe
2
Xerfi / November 2018
3
WHO
4
Survey by Fuméo.fr /December 2017 /Xerfi; based on
12 million smokers
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005635/en/
Contact:
KUMULUS VAPE Communications Director Vincent Baudoin v.baudoin@kumulusvape.fr Tel: +33 (0)6 10 84 52 59
ACTIFIN Press Officer Aminata Doucouré adoucoure@actifin.fr Tel: + 33 (0)1 56 88 11 23
ACTIFIN Financial Communication Julien Mouret jmouret@actifin.fr Tel: + 33 (0)1 56 88 11 14
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
